Na-Phenylbutyrate VAscular Trial

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions

Diabetes

Interventions

DRUG

Sodium Phenylbutyrate

will be compared to placebo

OTHER

Placebo

will be compared to NaPB

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Pennsylvania

OTHER

NCT06645769 - Na-Phenylbutyrate VAscular Trial | Biotech Hunter | Biotech Hunter